

Muscle weakness assessment in non-hypoxemic COPD out-patients at tertiary care hospitals

Faisal Faiyaz Zuberi¹, Bader Faiyaz Zuberi²,
Faiza Sadaqat Ali³, Nimrah Bader⁴

ABSTRACT

Objective: To determine frequency of Muscle Weakness in Non-Hypoxemic COPD out-patients and Comparison with age matched non-COPD Controls.

Methods: This cross-sectional study was conducted at OPD of Ojha Institute of Chest Diseases and Medicine, Dow University of Health Sciences, Karachi, Pakistan, during the period 8th September 2019 till 30th May 2020. Patients of both genders aged 25-70 years who were satisfying GOLD criteria for COPD and having SpO₂ ≥ 94% were included. An age matched control group was added as control. Hand Grip Strength (HGS) and Chair to Stand time (CST) were recorded.

Results: Two hundred fifty-six patients were inducted with aged and BMI matched group of non-COPD Control patients in ratio of 1:2 (n = 128). Comparison of HGS between Control and COPD Groups showed significant weakness in COPD group. Significant weakness in lower limbs in COPD Group with longer timings to complete the task. Mean FEV₁ had significant low values in COPD Group. Age correlated negatively with HGS & positively with CST. BMI correlated positively with FEV₁ and CST but negatively with HGS. HGS correlated positively with FEV₁ and no correlation was found with CST. No correlation was found of CST with FEV₁.

Conclusion: Muscle weakness in COPD patients was shown by simple validated bedside tools. The older COPD patients had less HGS and were slower in doing CST whereas those COPD ones who had higher FEV₁ had more HGS.

KEYWORDS: Sarcopenia, Hand grip strength, Chair to stand time, BMI, FEV₁.

Abbreviations:

COPD: Chronic Obstructive Pulmonary Disease, **BMI:** Body Mass Index, **FEV:** Forced Expiratory Volume in first second, **GOLD:** Global Initiative for Chronic Obstructive Lung Disease, **HGS:** Hand Grip Strength, **CST:** Chair to Stand Time.

doi: <https://doi.org/10.12669/pjms.37.2.3127>

How to cite this:

Zuberi FF, Zuberi BF, Ali FS, Bader N. Muscle weakness assessment in non-hypoxemic COPD out-patients at tertiary care hospitals. *Pak J Med Sci.* 2021;37(2):536-542. doi: <https://doi.org/10.12669/pjms.37.2.3127>

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

INTRODUCTION

Chronic Obstructive Pulmonary Disease (COPD) is affecting around 10% of population of over the age 40 years and 4% in general population.¹ Currently it is the fourth common cause of death in world and by 2030 it would become the third most common reason for mortality.² The Global Initiative for Chronic Obstructive Lung Disease (GOLD)³ defines COPD as “a common preventable and treatable disease characterized by persistent airflow limitation that is usually progressive and associated

Correspondence:

Faisal Faiyaz Zuberi,
Chest Unit-II,
Ojha Institute of Chest Diseases,
Dow University of Health Sciences,
Karachi, Pakistan.
Email: faisal@zuberi.net
faisal.zuberi@duhs.edu.pk

- * Received for Publication: June 25, 2020
- * Revision Received: December 7, 2020
- * Revision Accepted: December 25, 2020

with an enhanced chronic inflammatory response in the airways and lungs to noxious particles and gases".³ Among other factors, presence of sarcopenia is one of the factors for increased morbidity and mortality in COPD.⁴

Sarcopenia is related to increase further more complications as of osteopenia and related bone disease in COPD patients.⁵ Decreased muscle mass leads to muscle weakness that further deteriorate the quality of life and mobility in these patients. The impact of muscle weakness in COPD is not well documented in epidemiological studies and the exact nature of their relationship is still unclear. Decreased mobility leads to sedentary lifestyle and aggravates obesity which further leads to increase in complications including metabolic syndrome.⁶ Decrease in lean body mass is one of the factors and has been shown to be a reliable predictor of mortality in COPD.⁷ There is gradual decrease in muscle mass in COPD over the age of 50 years at the rate of 1-2% per year leading to frailty syndrome.⁷ This has been documented to occur in 20-40% of all COPD patients including 10-15% of those with normal weight.⁸ Decrease in exercise capacity in COPD limits the daily living physical activities thus increasing risk of exacerbations.⁸ Muscle strength is important factor determining physical activities and exercise capacity.

The current study was planned to document decrease in muscle strength in COPD in comparison with age matched non-controls in our population. This study is first time documentation of comparison of muscle strength in COPD from our area and will help to identify patients at risk thereby leading to better understanding and management of COPD. This study was conducted to determine frequency of muscle weakness in non-hypoxemic out-patients with COPD and comparison with age matched non-COPD controls.

METHODS

Operational Definitions:

COPD: Diagnosed with spirometry as per GOLD guideline of post-bronchodilator $FEV_1/FVC < 0.70$.⁹

Non-hypoxemia: Diagnosed if SpO_2 is $\geq 94\%$ on finger pulse oximetry.

Hand Grip Testing (HGS): Done using standard hand grip strength testing dynamometer (CAMRY, South El Monte, CA, USA). Patients were asked to squeeze the device by dominant hand with full force/strength that he/she can apply and hold for

03 seconds and reading on displayed were recorded in proforma. The procedure was repeated after one minute for two more times and highest value achieved was taken for analysis.

Chair to Stand Time (CST): Patients were asked to stand from chair and sit continuously without pause for five times. Time was measured in seconds using standard stopwatch.¹⁰

Body Mass Index (BMI): Calculated by formula $BMI = \text{weight (kg)} / \text{height (m)}^2$. Asian BMI classification was used in this study. < 18.5 for underweight, 18.5-22.9 for normal-weight, 23.0-27.5 for overweight, and > 27.5 for obese.¹¹

GOLD Classification of airflow limitation severity in COPD:⁹ (based on post-bronchodilator FEV_1)

GOLD 1 – Mild: $FEV_1 \geq 80\%$ predicted

GOLD 2 – Moderate: $50\% \leq FEV_1 < 80\%$ predicted

GOLD 3 – Severe: $30\% \leq FEV_1 < 50\%$ predicted

GOLD 4 – Very Severe: $FEV_1 < 30\%$ predicted

This cross-sectional study was conducted in out-patient department (OPD) of Ojha Institute of Chest Diseases and Medical OPD of Civil Hospital Karachi from 8th September 2019 till 30th May 2020. Using reported frequency of sarcopenia in COPD of 14.5%,¹² power of 95% and alpha of 0.01; sample size was calculated as 205. Sample size calculation was done by PASS 2019 software.

Convenience sampling technique was used. Study has ethical approval from IRB of Dow University of Health Sciences vide its letter # IRB-1419/DUHS/Approval/2019 dated 04 November 2019. Patients were informed about study protocol and possible adverse effects and given option to withdraw from study any time.

Inclusion Criteria: Out-patients of both genders of age 25-70 years were included after informed consent. Patients presenting with symptoms suggestive of airway disease were evaluated in OPD for COPD. COPD was diagnosed as per operational criteria.

Exclusion Criteria: Patients with finger pulse oximetry SpO_2 of $< 94\%$ were excluded. Patients with pulmonary tuberculosis, pleural effusion, heart failure, diagnosed cases of myopathy, polymyositis, arthritis, diabetes were also excluded.

Finger pulse oximetry was done of all patients satisfying COPD criteria and those with oxygen saturations of $\geq 94\%$ were included in study for further workup after informed consent. Demographics like age, gender, height and weight were recorded. Body mass index (BMI)

was calculated. Hand Grip Strength (HGS) was measured in kilograms, three readings were taken one minute apart. Best of three was selected for analysis. Five-times Chair to Stand (CST) time was measured in seconds. An age matched control group was added as control in a ratio of 1:2. Post bronchodilatation FEV₁ was recorded using Vitalograph spirometry machine.

Analysis: Age, BMI, HGS, CST & FEV₁ in both groups was compared by Student's t-test. Intra-group comparison of age, HGS, CST & FEV₁ on basis of gender was done using Student's t-test. BMI values were segregated into BMI Groups based on its classification and their frequencies were compared between two groups using χ^2 test. FEV₁ values were segregated into groups as defined by GOLD Classification and were compared between groups using χ^2 test. Significance level was set at ≤ 0.05 . SPSS version 25 was used for statistical analysis.

RESULTS

Two hundred fifty-six out-patients satisfying the selection criteria were inducted after informed consent were included in the study. An age matched group of non-COPD Control patients in ratio of 1:2 also inducted as control (n = 128). There was no significant difference between age of two groups and were adequately matched ($t(213.8) = -1.7, p = 0.084$). The difference in BMI in both groups was statistically insignificant and both groups were adequately matched ($t(336.6) = -1.86, p = .064$). Comparison of Mean FEV₁ in both groups with Student's t-test showed its significant low values in COPD Group ($t(382) = 27.3, p < 0.001$). Upper limb strength was measured with HGS and in comparison, of HGS between Control and COPD Groups showed significant weakness

in COPD group ($t(150.8) = 6.1, p < 0.001$). Lower limb strength was measured with CST and in comparison, with Student's t-test showed significant weakness in lower limbs in COPD Group with longer timings to complete the task ($t(333.1) = -23.4, p < 0.001$). Table-I.

The difference in age according to gender was not statistically significant ($t(126) = 1.8, p = .079$). There was significant difference in BMI among gender ($24.5 \pm 2.9 \text{ kg/m}^2 \text{ males vs } 23.2 \pm 4.0 \text{ kg/m}^2 \text{ females}$) ($t(125.8) = 2.2, p = 0.030$). Gender comparison of FEV₁ ($98.8 \pm 4.7 \text{ males vs } 92.3 \pm 13.7 \text{ females}$) showed the difference was significant ($t(98.3) = 3.8, p < .001$). The HGS in females was significantly less ($22.5 \pm 2.5 \text{ kg females vs } 40.0 \pm 9.9 \text{ kg males}$) on Student's t-test ($t(55.5) = 12.6, p < 0.001$). The CST was significantly quick in males ($7.0 \pm 0.8 \text{ sec males vs } 7.9 \pm 1.1 \text{ sec females}$) ($t(125.6) = -5.5, p < 0.001$). Table-II.

Difference in age ($44.3 \pm 7.5 \text{ years males vs } 38.8 \pm 9.2 \text{ years females}$) was statistically significant ($t(254) = 4.6, p < .001$). There was no significant difference in BMI among gender ($t(80.8) = 1.8, p = .074$). No significant difference was observed in FEV₁ among gender ($t(254) = .7, p = .469$). Mean HGS in females was significantly less ($22.9 \pm 3.8 \text{ kg females vs } 25.8 \pm 6.4 \text{ kg males}$) on Student's t-test ($t(66.4) = -3.3, p = 0.002$). The difference in CST was not significant between gender ($t(254) = -1.1, p = .276$). Table-II.

BMI & FEV₁ Categories: Patients were categorized into BMI categories as described in methods. Most common frequency was found in normal BMI groups. Comparison of BMI Categories between Control and COPD groups by χ^2 test showed no significant differences, details are given in Table-III. Cross-tabulation of GOLD Grade according to Groups showed most common frequency in

Table-I: Comparison of Age, HGS, CST & FEV1 time between Control and COPD groups.

	Group	Mean	\pm SD	t	Sig.	95% CI
Age (years)	Control	41.4	10.1	-1.7	0.084	-3.81 to .24
	COPD	43.1	8.2			
BMI (Kg/m ²)	Control	23.7	3.7	1.9	0.064	-0.05 to 1.74
	COPD	22.9	5.1			
FEV ₁	Control	95.0	11.4	27.3	< 0.001*	1.22 to 30.33
	COPD	62.2	10.9			
HGS (kg)	Control	29.6	10.8	6.1	< 0.001*	4.08 to 8.04
	COPD	23.5	4.6			
CST (sec)	Control	7.6	1.1	-23.4	< 0.001*	-3.44 to -2.90
	COPD	10.7	1.5			

* Significant Level ≤ 0.05 .

Table-II: Intra-group comparison of age, HGS, CST & FEV₁ between gender in Control & COPD groups with Student's t-test.

Group	Test	Gender	Mean	±SD	Sig.	95% CI
Control Group	Age	Male	43.2	9.8	0.079	-0.37 to 6.73
		Female	40.1	10.1		
	BMI	Male	24.5	2.9	0.030*	0.13 to 2.55
		Female	23.2	4.0		
	HGS	Male	40.18	9.73	< 0.001**	14.74 to 20.34
		Female	22.31	2.26		
CST	Male	7.00	0.81	< 0.001**	-1.26 to -.59	
	Female	7.93	1.11			
COPD Group	FEV ₁	Male	98.8	4.7	< 0.001*	1.70 to 3.10
		Female	92.3	13.7		
	Age	Male	44.3	7.5	< 0.001	3.17 to 7.88
		Female	38.8	9.2		
	BMI	Male	23.2	4.9	0.074	-0.15 to 3.12
		Female	21.7	5.6		
HGS	Male	25.8	6.4	0.002*	-4.70 to -1.33	
	Female	22.9	3.8			
CST	Male	10.7	1.5	0.276	-0.70 to .20	
	Female	10.9	1.6			
FEV ₁	Male	62.5	11.0	0.469	-2.06 to 4.45	
	Female	61.3	10.5			

* Significance level $P \leq 0.05$.

Control Group of Mild Class (90.6%) and in COPD Group most common frequency was found in Moderate Class (53.6%). Significant difference in frequency was observed by χ^2 test. Table-IV.

Correlation of Age, BMI, HGS, CST & FEV₁ was done using Pearson Correlation test and it showed significant correlation between various parameters. Age correlated negatively with HGS & positively with CST, while no correlation was found with BMI & FEV₁. BMI correlated positively with FEV₁ and CST but negatively with

HGS. HGS correlated positively with FEV₁ and no correlation was found with CST. No correlation was found of CST with FEV₁ Table-V.

DISCUSSION

Our study demonstrated important findings that muscle power in COPD Group was less as compared to controls. Muscle weakness plays a pivotal role in the clinical outcome in COPD patients. Muscle weakness is simply the assessment of functionality of muscle and it is assessed by

Table-III: Cross-tabulation of BMI Categories (Asian) according to Groups with χ^2 Test.

			Group		Total
			Control	COPD	
BMI Groups	Underweight	N	7	23	30
	< 18.5	%	5.5%	9.0%	7.8%
	Normal	N	53	102	155
	18.5-22.9	%	41.4%	39.8%	40.4%
	Overweight	N	44	94	138
	23.0-27.5	%	34.4%	36.7%	35.9%
	Obese	N	24	37	61
	> 27.5	%	18.8%	14.5%	15.9%
Total		N	128	256	384
		%	100.0%	100.0%	100.0%

 χ^2 Test = (3, N = 384) = 2.5, p = 0.471.Table-IV: Cross-tabulation of GOLD Grade according to Groups with χ^2 Test.

			Group		Total
			Control	COPD	
GOLD Grade	Mild	N	116	6	122
	$\geq 80\%$	%	90.6%	2.3%	31.8%
	Moderate	N	12	194	206
	50 to <80%	%	9.4%	75.8%	53.6%
	Severe	N	0	56	56
	30 to <50%	%	0.0%	21.9%	14.6%
	Very Severe	N	0	0	0
	<30%	%	0.0%	0.0%	0.0%
Total		N	128	256	384
		%	100.0%	100.0%	100.0%

 χ^2 Test = (2, N = 384) = 307.5, p < 0.001.

Table-V: Pearson Linear Correlation of Age, BMI, HGS, CST & FEV₁.

		Correlations				
		Age	BMI	HGS	CST	FEV ₁
Age (years)	Pearson Correlation	1	0.034	-0.586**	0.294**	0.097
	Sig. (2-tailed)		0.584	0.000	0.000	0.121
BMI	Pearson Correlation	0.034	1	-0.265**	0.205**	0.374**
	Sig. (2-tailed)	0.584		0.000	0.001	0.000
HGS (kg)	Pearson Correlation	-0.586**	-0.265**	1	-0.059	0.179**
	Sig. (2-tailed)	0.000	0.000		0.345	0.004
CST (sec)	Pearson Correlation	0.294**	0.205**	-0.059	1	0.059
	Sig. (2-tailed)	0.000	0.001	0.345		0.349
FEV ₁	Pearson Correlation	0.097	0.374**	0.179**	0.059	1
	Sig. (2-tailed)	0.121	0.000	0.004	0.349	

** : Correlation is significant at the 0.01 level (2-tailed).

Pearson correlation values with (-) sign means negative correlation.

simple and easy tools. Although recently the term sarcopenia has been rejuvenated by Bulow et al., who added muscle strength and physical function like gait speed to the definition of sarcopenia.^{13,14} Muscle strength in upper limbs is assessed by hand grip¹⁵ in COPD patients, while in lower limbs it is assessed by different tools like six minutes' walk test (6MWT), timed up and go (TUG) test.¹⁶

and chair to stand time (CST). Sarcopenia and muscle weakness in COPD is associated with many disorders like reduced bone mineral density, osteopenia and osteoporosis.⁵ It is shown to be a common finding in stable COPD patients and is also associated with lower exercise tolerance in these patients.¹⁷ Our findings were consistent with the findings of Miroslav Kovarik et al., where they found that hand grip strength and lower limbs power both were less in COPD patients as compared to healthy control group.¹⁸ For assessing lower limb function, they utilized 6MWT but in our study, we used CST to assess lower limb function which is equally sensitive.^{19,20}

We have established that reduced muscle strength was associated with reduced pulmonary function, as we found positive correlation between HGS and FEV₁. This finding is similar to the study of Han CH et al.²¹ HGS test not only has demonstrated association with mortality in general population,²² but also in other disorders including cirrhosis of liver.²³ It has become an attractive tool for predicting prognosis in COPD, both in clinical practice as well as in research purpose, and is considered to be even better than 6 MWT.²⁴ The relationship between HGS and pulmonary function testing showed different results in previous studies as no difference in HGS in COPD patients as compared

to non COPD subjects,²⁵ while in other studies lower HGS in COPD patients.²⁶ These contradictory findings might be due to enrolling COPD patients with different severity, as GOLD Grade 3-4 has significantly lower HGS²⁶ than GOLD Grade 1-2. Furthermore, some studies used only GOLD Grade and each GOLD Grade encompass a wide range of FEV₁. So, we used FEV₁%, which as a continuous variable is more sensitive when evaluating HGS in relation to COPD severity.

Gender analysis in our study highlighted that in control group males were stronger than females, both in term of HGS and quick CST. Similarly, males in COPD group had good HGS than female COPD patients. This finding was similar to previous studies.^{21,16} In our study, in COPD group, females did not show comparative weakness in lower limbs as compared to males, when it comes to CST test. This might be due the fact that in our study, most of the females in COPD group were slightly younger than males. Also, females in COPD group had comparative lower BMI than males in this group. Thus, reproductive age, and lower BMI in females could explain this finding.

Another particularly important finding in our study was that majority of COPD patients had above normal BMI (36.7% overweight and 14.5% obese), with a high mean BMI of 22.9 Kg/m². This contrasts with other studies, where they found that majority of COPD patients were underweight. Effect of BMI on FEV₁ and clinical outcome of COPD remains controversial. Majority of studies highlighted that lower BMI had been associated with high mortality in COPD patients,²⁷ while fewer studies have highlighted that over-weight and obesity is more prevalent

in COPD and imposes worse clinical outcomes, low muscle strength in terms of 6MWD and more acute exacerbation of COPD.^{28,29} Our study showed positive correlation of BMI with CST and FEV₁ but negative correlation with HGS in COPD patients. Our finding on BMI were consistent with Lambert AA et al., where he found that 35% of COPD patients were obese, having decrease muscle strength in terms of 6MWT.²⁹ This obesity in COPD group in our study might be due to sedentary lifestyle from decreased overall muscle strength. Our study also showed positive correlation of BMI with FEV₁ meaning patients with low BMI had low FEV₁ and were in higher GOLD Grade. This effect was also shown by Lim JU et al that Asian BMI classification was more relevant in Asian population.³⁰ We also used Asian BMI Classification and found that majority (75.8%) of COPD patients were having moderate airflow limitation (GOLD Grade 2 with a mean post-bronchodilator FEV₁ was 62.2), followed by severe (21.9%), i.e., GOLD Grade 3.

Main strength of our study is, we used simple and reliable tools to assess muscle strength in COPD patients which can be done easily in clinics. We assessed muscle weakness in both upper as well as lower limbs simultaneously by HGS test and CST test respectively for overall physical functional limitation in COPD patients and compared them with aged matched non COPD group. Whereas most of the previous studies checked muscle function with only single test either HGS or CST or 6MWT. We checked FEV₁ % as a continuous variable and established its association between muscle weakness and COPD clinical outcome, rather than using only GOLD Grade as a categorical variable, for predicting clinical outcome in COPD patients. In our study correlation between HGS and CST was not statistically significant, reason being the disease may affect differentially upper and lower limbs although both tests individually performed very well in assessment.³¹

Limitations of the study: It is its cross-sectional study design.

CONCLUSION

We demonstrated muscle weakness in COPD out-patients by simple validated tools. The older COPD patients had less HGS and were slower in doing CST whereas those who had higher FEV₁ had more HGS. By understanding the magnitude of muscle weakness in COPD patients, future

studies can be carried out and focused on strategies to minimize and potentially reverse muscle weakness for better clinical outcome in these patients.

Acknowledgement: Authors wish to acknowledge help and support extended by paramedical and clerical staff in conducting this study.

Disclosure Statement/Funding: All authors report no disclosure for this study neither any financial support nor grant was obtained for it.

REFERENCES

- Hurd S. The impact of COPD on lung health worldwide: epidemiology and incidence. *Chest* 2000;117:1S-4S. doi:10.1378/chest.117.2_suppl.1s
- Shaikh M, Sood RG, Sarkar M, Thakur V. Quantitative Computed Tomography (CT) Assessment of Emphysema in Patients with Severe Chronic Obstructive Pulmonary Disease (COPD) and its Correlation with Age, Sex, Pulmonary Function Tests, BMI, Smoking, and Biomass Exposure. *Pol J Radiol*. 2017;82:760-766. doi: 10.12659/PJR.903278
- Albitar HAH, Iyer VN. Adherence to Global Initiative for Chronic Obstructive Lung Disease guidelines in the real world: current understanding, barriers, and solutions. *Curr Opin Pulm Med*. 2020;26:149-154. doi: 10.1097/MCP.0000000000000655
- Costa TM, Costa FM, Moreira CA, Rabelo LM, Boguszewski CL, Borba VZ. Sarcopenia in COPD: relationship with COPD severity and prognosis. *J Bras Pneumol*. 2015;41:415-421. doi: 10.1590/S1806-37132015000000040
- Hwang JA, Kim YS, Leem AY, Park MS, Kim SK, Chang J, et al. Clinical Implications of Sarcopenia on Decreased Bone Density in Men With COPD. *Chest*. 2017;151:1018-1027. doi: 10.1016/j.chest.2016.12.006
- Jiang B, Chen Y, Zhou K, Zheng Y, Chen Y, Li Q, et al. Comparison of Abdominal Obesity and Fatty Liver and Their Association with Insulin Resistance and Metabolic Syndrome in Chinese Adults. *Obesity (Silver Spring)*. 2019;27:707-715. doi: 10.1002/oby.22432
- Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive pulmonary disease. *Am J Clin Nutr*. 2005;82:53-59. doi: 10.1093/ajcn.82.1.53
- Maltais F. Body composition in COPD: looking beyond BMI. *Int J Tuberc Lung Dis*. 2014;18:3-4. doi:10.5588/ijtld.13.0868
- Neumeier A, Keith R. Clinical Guideline Highlights for the Hospitalist: The GOLD and NICE Guidelines for the Management of COPD. *J Hosp Med*. 2020;15:e1-e2. doi: 10.12788/jhm.3368
- Tapper EB, Derstine B, Baki J, Su GL. Bedside Measures of Frailty and Cognitive Function Correlate with Sarcopenia in Patients with Cirrhosis. *Dig Dis Sci*. 2019;64:3652-3659. doi: 10.1007/s10620-019-05713-4
- Verma M, Rajput M, Kishore K, Kathirvel S. Asian BMI criteria are better than WHO criteria in predicting Hypertension: A cross-sectional study from rural India. *J Family Med Prim Care*. 2019;8:2095-2100. doi:10.4103/jfmpc.jfmpc_257_19

12. Jones SE, Maddocks M, Kon SS, Canavan JL, Nolan CM, Clark AL, et al. Sarcopenia in COPD: prevalence, clinical correlates and response to pulmonary rehabilitation. *Thorax*. 2015;70:213-218. doi: 10.1136/thoraxjnl-2014-206440
13. Bulow J, Ulijaszek SJ, Holm L. Rejuvenation of the term sarcopenia. *J Appl Physiol* (1985). 2019;126:255-256. doi: 10.1152/jappphysiol.00400.2018
14. Langer HT, Mossakowski AA, Baar K, Alcazar J, Martin-Rincon M, Alegre LM, et al. Commentaries on Viewpoint: Rejuvenation of the term sarcopenia. *J Appl Physiol* (1985). 2019;126:257-262. doi: 10.1152/jappphysiol.00816.2018
15. Alley DE, Shardell MD, Peters KW, McLean RR, Dam TT, Kenny AM, et al. Grip strength cutpoints for the identification of clinically relevant weakness. *J Gerontol A Biol Sci Med Sci*. 2014;69:559-566. doi: 10.1093/gerona/glu011
16. Albarrati AM, Gale NS, Enright S, Munnery MM, Cockcroft JR, Shale DJ. A simple and rapid test of physical performance in chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Disease*. 2016;11:1785.
17. Byun MK, Cho EN, Chang J, Ahn CM, Kim HJ. Sarcopenia correlates with systemic inflammation in COPD. *Int J Chron Obstruct Pulmon Dis*. 2017;12:669-675. doi: 10.2147/COPD.S130790
18. Kovarik M, Joskova V, Patkova A, Koblizek V, Zadak Z, Hronek M. Hand grip endurance test relates to clinical state and prognosis in COPD patients better than 6-minute walk test distance. *Int J Chron Obstruct Pulmon Disease*. 2017;12:3429.
19. Bennell K, Dobson F, Hinman R. Measures of physical performance assessments: Self-Paced Walk Test (SPWT), Stair Climb Test (SCT), Six-Minute Walk Test (6MWT), Chair Stand Test (CST), Timed Up & Go (TUG), Sock Test, Lift and Carry Test (LCT), and Car Task. *Arthritis Care Res (Hoboken)*. 2011;63 Suppl 11:S350-S370. doi: 10.1002/acr.20538
20. Nishimura T, Arima K, Okabe T, Mizukami S, Tomita Y, Kanagae M, et al. Usefulness of chair stand time as a surrogate of gait speed in diagnosing sarcopenia. *Geriatr Gerontol Int* 2017;17:668-669. doi: 10.1111/ggi.12882
21. Han CH, Chung JH. Association between hand grip strength and spirometric parameters: Korean National health and Nutrition Examination Survey (KNHANES). *J Thorac Disease*. 2018;10:6002.
22. Leong DP, Teo KK, Rangarajan S, Lopez-Jaramillo P, Avezum A, Jr., Orlandini A, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. *Lancet*. 2015;386:266-273. doi: 10.1016/S0140-6736(14)62000-6
23. Hanai T, Shiraki M, Imai K, Suetsugu A, Takai K, Moriwaki H, et al. Reduced handgrip strength is predictive of poor survival among patients with liver cirrhosis: A sex-stratified analysis. *Hepatol Res*. 2019;49:1414-1426. doi: 10.1111/hepr.13420
24. Kovarik M, Joskova V, Patkova A, Koblizek V, Zadak Z, Hronek M. Hand grip endurance test relates to clinical state and prognosis in COPD patients better than 6-minute walk test distance. *Int J Chron Obstruct Pulmon Dis*. 2017;12:3429-3435. doi: 10.2147/COPD.S144566
25. Jeong M, Kang HK, Song P, Park HK, Jung H, Lee SS, et al. Hand grip strength in patients with chronic obstructive pulmonary disease. *Int J Chron Obstruct Pulmon Dis*. 2017;12:2385-2390. doi: 10.2147/COPD.S140915
26. Strandkvist VJ, Backman H, Röding J, Stridsman C, Lindberg A. Hand grip strength is associated with forced expiratory volume in 1 second among subjects with COPD: report from a population-based cohort study. *Int J Chron Obstruct Pulmon Disease*. 2016;11:2527.
27. Cao C, Wang R, Wang J, Bunjhoo H, Xu Y, Xiong W. Body mass index and mortality in chronic obstructive pulmonary disease: a meta-analysis. *PLoS One* 2012;7:e43892. doi: 10.1371/journal.pone.0043892
28. Verberne LDM, Leemrijse CJ, Swinkels ICS, van Dijk CE, de Bakker DH, Nielen MMJ. Overweight in patients with chronic obstructive pulmonary disease needs more attention: a cross-sectional study in general practice. *NPJ Prim Care Respir Med*. 2017;27:63. doi: 10.1038/s41533-017-0065-3
29. Lambert AA, Putcha N, Drummond MB, Boriek AM, Hanania NA, Kim V, et al. Obesity is associated with increased morbidity in moderate to severe COPD. *Chest*. 2017;151:68-77.
30. Lim JU, Lee JH, Kim JS, Hwang YI, Kim TH, Lim SY, et al. Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patients. *Int J Chron Obstruct Pulmon Dis*. 2017;12:2465-2475. doi: 10.2147/COPD.S141295
31. Ha YC, Yoo JI, Park YJ, Lee CH, Park KS. Measurement of Uncertainty Using Standardized Protocol of Hand Grip Strength Measurement in Patients with Sarcopenia. *J Bone Metab* 2018;25(4):243-249 DOI: 10.11005/jbm.2018.25.4.243.

Authors' Contribution:

FFZ, BFZ, FSA, NB: Conception, design, responsible and accountable for the accuracy or integrity of the work.

FFZ: Administrative support.

FSA: Provision of study materials or patients.

BFZ, NB: Collection and assembly of data.

NB, BFZ, FFZ: Data analysis and interpretation.

FFZ, BFZ, FSA, NB: Manuscript writing.

FFZ, BFZ, FSA, NB: Final approval of manuscript.

Authors:

1. Faisal Faiyaz Zuberi, Ojha Institute of Chest Diseases,
 2. Bader Faiyaz Zuberi, Department of Medicine, Dow Medical College,
 3. Faiza Sadaqat Ali, Department of Medicine, Dow Medical College,
 4. Nimrah Bader, Department of Internal Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
- 1-3: Dow University of Health Sciences, Karachi, Pakistan.